Table 3. ELISA titers to the indicated antigens.
| Group | Immunogen prime/boost* | MPER titer** (s.e.m.) | Immunogen titer** (s.e.m.) |
|---|---|---|---|
| Prime-boost study #1 | |||
| N1-1 | gp140/gp140 | n.d. | 2190*** |
| N1-2 | FDAB4/FDAB4 | 46 (16) | 37,954 (588) |
| N1-3 | gp140/FDAB4 | n.d. | 6830*** (139) |
| N1-4 | FDAB4/gp140 | 28 (8) | 5655*** (116) |
| N1-7 | DNA gp160/ gp140 | n.d. | 2370*** (116) |
| N1-8 | DNA gp160/FDAB4 | n.d. | 28,304***(488) |
| Prime-boost study #2 | |||
| N2-1 | FDA13/FDA13 | 46 (21) | 40,679(46) |
| N2-2 | FDA18/FDA18 | 23 (12) | 42,579 (4363) |
| N2-3 | DNAgp160/FDA18 | 44 (12) | 31,129 (1337) |
| N2-4 | DNAfdaB12/FDA18 | 101 (23) | 32,429 (513) |
| N2-5 | FDA13/gp140 | n.d. | 4835 (99) |
| N2-6 | FDA18/gp140 | n.d. | 4515 (171) |
| N2-7 | DNAfdaB12/FDA13 | 526 (162) | 38,304 (1938) |
| N2-8 | DNAfdaB12/gp140 | n.d. | 681 (23) |
| N2-9 | DNAgp160/FDA13 | 84 (29) | 34,654 (4138) |
| Prime-boost study #3 | |||
| N3-1 | DNAfdaFI3/FDA22 | 64 (20) | 52,529 (63) |
| N3-2 | DNA fdaB5/FDA22 | 35 (4) | 56,754 (3412) |
| N3-3 | DNAgp160/FDA22 | n.d. | 51,204 (1712) |
| N3-4 | DNAfdaFI3/FDA18 | n.d. | 38,254 (312) |
| N3-5 | DNAfdaB5/FDA18 | 24 (7) | 38,979 (3137) |
| N3-6 | DNAgp160/FDA18 | n.d. | 32,954 (2538) |
| N3-7 | DNA fdaFI3/FDA20 | 548 (107) | 79,054 (938) |
| N3-8 | DNAfdaB5/FDA20 | 51 (16) | 64,079 (1537) |
| N3-9 | DNAgp160/FDA20 | n.d. | 68, 354 (388) |
| N3-10 | FDA22/FDA22 | n.d. | 48,579 (2937) |
| N3-11 | FDA18/FDA18 | 35 (7) | 42,679 (2987) |
| N3-12 | FDA20/FDA20 | n.d. | 50,479 (1013) |
| Prime-boost study #4 | |||
| N4-1 | DNAfdaB12+FDA26/FDA26 | 42 (17) | 23,954 (2238) |
| N4-2 | FDA26/FDA26 | n.d. | 24,254 (588) |
*Two primes giving at weeks 0 and 8 followed by boosts at weeks 12 and 24 using the indicated immunogens mixed with MF59 adjuvant.
** titer = mean ELISA unit (EU, endpoint dilution x O.D. 450nm) to the MPER peptide or protein immunogen using sera following the final boost.
*** tested against FDAB4 immunogen. s.e.m. = standard deviation; n.d. = not detectable above background